Phio Pharmaceuticals says PH-762 is well-tolerated in Phase 1b skin cancer trial
PHIO•Phio Pharmaceuticals said findings from its Phase 1b trial suggest PH-762 is well tolerated and could reduce the extent of surgery for cutaneous squamous cell carcinoma.
1. Trial findings and next steps
Phio Pharmaceuticals will present final Phase 1b results for PH-762 at the Society for Immunotherapy of Cancer’s annual meeting in Phoenix on November 7, 2026. The company plans a Phase 2b study in the first half of 2027 to further evaluate safety and efficacy.
